51
|
Welling M, Stokkel M, Balter J, Sarda-Mantel L, Meulemans A, Le Guludec D. The many roads to infection imaging. Eur J Nucl Med Mol Imaging 2008; 35:848-9. [PMID: 18188558 PMCID: PMC2668546 DOI: 10.1007/s00259-007-0695-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
52
|
Pappas V. Working together to create the future. J Nucl Med 2008; 49:18N. [PMID: 18322114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
|
53
|
McEwan AJ, Van Brocklin HF, Divgi C. Action plan for emerging molecular imaging technologies. J Nucl Med 2008; 49:37N-40N. [PMID: 18245736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023] Open
|
54
|
Abstract
The development of nanotechnology relies heavily on the ability to observe and probe at molecular scales. Thus, breakthroughs in instrumentation and techniques play a significant role in the advancement in nanoscience. In this article, we survey recent developments in observing, trapping, and probing single molecules in solution. We give particular attention to patents that cover enabling instrumentation in each of these related areas including, respectively, fluorescence imaging, optical tweezers, and anti-Brownian traps. We conclude by highlighting a broad trend in the literature and patent base from observation toward active interrogation of single molecules in solution.
Collapse
|
55
|
Holt KB. Diamond at the nanoscale: applications of diamond nanoparticles from cellular biomarkers to quantum computing. PHILOSOPHICAL TRANSACTIONS. SERIES A, MATHEMATICAL, PHYSICAL, AND ENGINEERING SCIENCES 2007; 365:2845-61. [PMID: 17855222 DOI: 10.1098/rsta.2007.0005] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
Although nanocrystalline diamond powders have been produced in industrial quantities, mainly by detonation synthesis, for many decades their use in applications other than traditional polishing and grinding have been limited, until recently. This paper presents the wide-ranging applications of nanodiamond particles to date and discusses future research directions in this field. Owing to the recent commercial availability of these powders and the present interest in nanotechnology, one can predict a huge increase in research with these materials in the very near future. However, to fully exploit these materials, fundamental as well as applied research is required to understand the transition between bulk and surface properties as the size of particles decreases.
Collapse
|
56
|
Buscombe JR, Signore A. Has radio-targeting come of age? Report of the 18th IRIST meeting. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF... 2007; 51:290-1. [PMID: 17464279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
|
57
|
|
58
|
|
59
|
Post MJD. A new era in neuroradiology: ex vivo validation of in vivo imaging research. AJNR Am J Neuroradiol 2007; 29:212-3. [PMID: 17989368 DOI: 10.3174/ajnr.a0837] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
60
|
Cai W, Chen X. Nanoplatforms for targeted molecular imaging in living subjects. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2007; 3:1840-54. [PMID: 17943716 DOI: 10.1002/smll.200700351] [Citation(s) in RCA: 351] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Molecular or personalized medicine is the future of patient management and molecular imaging plays a key role towards this goal. Recently, nanoplatform-based molecular imaging has emerged as an interdisciplinary field, which involves chemistry, engineering, biology, and medicine. Possessing unprecedented potential for early detection, accurate diagnosis, and personalized treatment of diseases, nanoplatforms have been employed in every single biomedical imaging modality, namely, optical imaging, computed tomography, ultrasound, magnetic resonance imaging, single-photon-emission computed tomography, and positron emission tomography. Multifunctionality is the key advantage of nanoplatforms over traditional approaches. Targeting ligands, imaging labels, therapeutic drugs, and many other agents can all be integrated into the nanoplatform to allow for targeted molecular imaging and molecular therapy by encompassing many biological and biophysical barriers. In this Review, we will summarize the current state-of-the-art of nanoplatforms for targeted molecular imaging in living subjects.
Collapse
|
61
|
Abstract
Cancer nanotechnology is an interdisciplinary area of research in science, engineering, and medicine with broad applications for molecular imaging, molecular diagnosis, and targeted therapy. The basic rationale is that nanometer-sized particles, such as semiconductor quantum dots and iron oxide nanocrystals, have optical, magnetic, or structural properties that are not available from molecules or bulk solids. When linked with tumor targeting ligands such as monoclonal antibodies, peptides, or small molecules, these nanoparticles can be used to target tumor antigens (biomarkers) as well as tumor vasculatures with high affinity and specificity. In the mesoscopic size range of 5-100 nm diameter, nanoparticles also have large surface areas and functional groups for conjugating to multiple diagnostic (e.g., optical, radioisotopic, or magnetic) and therapeutic (e.g., anticancer) agents. Recent advances have led to bioaffinity nanoparticle probes for molecular and cellular imaging, targeted nanoparticle drugs for cancer therapy, and integrated nanodevices for early cancer detection and screening. These developments raise exciting opportunities for personalized oncology in which genetic and protein biomarkers are used to diagnose and treat cancer based on the molecular profiles of individual patients.
Collapse
|
62
|
Gupta AK, Naregalkar RR, Vaidya VD, Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine (Lond) 2007; 2:23-39. [PMID: 17716188 DOI: 10.2217/17435889.2.1.23] [Citation(s) in RCA: 394] [Impact Index Per Article: 23.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Magnetic nanoparticles with appropriate surface coatings are increasingly being used clinically for various biomedical applications, such as magnetic resonance imaging, hyperthermia, drug delivery, tissue repair, cell and tissue targeting and transfection. This is because of the nontoxicity and biocompatibility demand that mainly iron oxide-based materials are predominantly used, despite some attempts to develop 'more magnetic nanomaterials' based on cobalt, nickel, gadolinium and other compounds. For all these applications, the material used for surface coating of the magnetic particles must not only be nontoxic and biocompatible but also allow a targetable delivery with particle localization in a specific area. Magnetic nanoparticles can bind to drugs and an external magnetic field can be applied to trap them in the target site. By attaching the targeting molecules, such as proteins or antibodies, at particles surfaces, the latter may be directed to any cell, tissue or tumor in the body. In this review, different polymers/molecules that can be used for nanoparticle coating to stabilize the suspensions of magnetic nanoparticles under in vitro and in vivo situations are discussed. Some selected proteins/targeting ligands that could be used for derivatizing magnetic nanoparticles are also explored. We have reviewed the various biomedical applications with some of the most recent uses of magnetic nanoparticles for early detection of cancer, diabetes and atherosclerosis.
Collapse
|
63
|
Lawrie GA, Robinson J, Corrie S, Ford K, Battersby BJ, Trau M. Multiplexed microsphere diagnostic tools in gene expression applications: factors and futures. Int J Nanomedicine 2007; 1:195-201. [PMID: 17722536 PMCID: PMC2426781 DOI: 10.2147/nano.2006.1.2.195] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Microarrays have received significant attention in recent years as scientists have firstly identified factors that can produce reduced confidence in gene expression data obtained on these platforms, and secondly sought to establish laboratory practices and a set of standards by which data are reported with integrity. Microsphere-based assays represent a new generation of diagnostics in this field capable of providing substantial quantitative and qualitative information from gene expression profiling. However, for gene expression profiling, this type of platform is still in the demonstration phase, with issues arising from comparative studies in the literature not yet identified. It is desirable to identify potential parameters that are established as important in controlling the information derived from microsphere-based hybridizations to quantify gene expression. As these evolve, a standard set of parameters will be established that are required to be provided when data are submitted for publication. Here we initiate this process by identifying a number of parameters we have found to be important in microsphere-based assays designed for the quantification of low abundant genes which are variable between studies.
Collapse
|
64
|
Persil O, Hud NV. Harnessing DNA intercalation. Trends Biotechnol 2007; 25:433-6. [PMID: 17825446 DOI: 10.1016/j.tibtech.2007.08.003] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2007] [Revised: 07/05/2007] [Accepted: 08/23/2007] [Indexed: 10/22/2022]
Abstract
Numerous small molecules are known to bind to DNA through base pair intercalation. Fluorescent dyes commonly used for nucleic acid staining, such as ethidium, are familiar examples. Biological and physical studies of DNA intercalation have historically been motivated by mutation and drug discovery research. However, this same mode of binding is now being harnessed for the creation of novel molecular assemblies. Recent studies have used DNA scaffolds and intercalators to construct supramolecular assemblies that function as fluorescent 'nanotags' for cell labeling. Other studies have demonstrated how intercalators can be used to promote the formation of otherwise unstable nucleic acid assemblies. These applications illustrate how intercalators can be used to facilitate and expand DNA-based nanotechnology.
Collapse
|
65
|
Lucignani G. Imaging biomarkers: from research to patient care—a shift in view. Eur J Nucl Med Mol Imaging 2007; 34:1693-7. [PMID: 17823797 DOI: 10.1007/s00259-007-0569-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
66
|
|
67
|
Shi ZD, Wu H, Ruddy B, Griffiths GL. Imaging Probe Development Center: a National Institutes of Health core synthesis resource for imaging probes. JOURNAL OF BIOMEDICAL OPTICS 2007; 12:051502. [PMID: 17994866 DOI: 10.1117/1.2778702] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The Imaging Probe Development Center (IPDC) has been set up under the auspices of the National Institutes of Health (NIH) Roadmap as part of the molecular libraries and imaging initiatives. It comprises a core synthesis facility dedicated to the preparation of imaging probes, initially for intramural NIH scientists, and later, for the extramural scientific community. The facility opened fully in late 2006, in refurbished laboratories in Rockville, Maryland, and a staff of around a dozen was recruited into place by early 2007; the director was hired in late 2005. The IPDC provides a mechanism for the production of sensitive probes for use by imaging scientists who cannot obtain such probes commercially. The probes to be made will encompass all major imaging modalities including radionuclide, magnetic resonance, and optical. The operation of the IPDC is outlined, together with the results of interim achievements while the IPDC maintained a small temporary laboratory in Bethesda. As of December 2006, a total of eleven probe compositions had been made, and several of these are described with particular mention of those probes intended for use in optical applications.
Collapse
|
68
|
Fighting cancer: the potential of quantum dots and rods. Nanomedicine (Lond) 2007; 2:149-52. [PMID: 17716117 DOI: 10.2217/17435889.2.2.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
69
|
|
70
|
Van Laere K. In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans. Eur J Nucl Med Mol Imaging 2007; 34:1719-26. [PMID: 17643242 DOI: 10.1007/s00259-007-0505-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
71
|
Hampel H, Teipel SJ, Bürger K. [Neurobiological early diagnosis of Alzheimer's disease]. DER NERVENARZT 2007; 78:1310-8. [PMID: 17611728 DOI: 10.1007/s00115-007-2317-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
In order to improve diagnosis of Alzheimer's disease (AD), candidate biological markers in CSF as well as structural and functional imaging were investigated. Biomarkers are clearly needed to support detection of incipient AD in subjects with mild cognitive impairment (MCI). To date the most promising core candidate markers are total and hyperphosphorylated tau protein and amyloid beta peptides in the CSF, as well as hippocampus and whole brain volumetry using MRI. None of the candidates has been finally validated and established for clinical routine so far. International controlled multicenter cooperative studies are ongoing to further develop these core diagnostic marker candidates (phase III). The core markers are reviewed in detail. Promising novel approaches are discussed.
Collapse
|
72
|
Retz M, Lehmann J, Nawroth R, Gschwend JE. [The latest news on bladder cancer]. Urologe A 2007; 46:727-8, 730-2. [PMID: 17576529 DOI: 10.1007/s00120-007-1370-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
A review of the current literature provides new scientific insights into the diagnosis, prognosis and novel molecular targets for bladder cancer. The new WHO classification refines our staging system and influences treatment options. International clinical databases provide new tools for calculating the individual risk for bladder cancer recurrence and progression. Systematic gene cluster analysis defines multimarker panels that can serve as robust predictors of outcome. Discoveries of new signaling pathways in bladder cancer are leading to novel molecular targets for innovative therapies.
Collapse
|
73
|
Schillaci O. PET probes and oncological surgery: a productive new marriage for nuclear medicine? Eur J Nucl Med Mol Imaging 2007; 34:1530-3. [PMID: 17546457 DOI: 10.1007/s00259-007-0482-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
74
|
Maggi A, Salvatore M. Molecular imaging. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF... 2007; 51:95. [PMID: 17420710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
|
75
|
Abstract
Mitochondrial research has made an enormous leap since mitochondrial DNA mutations were identified as a primary cause for human diseases in 1988 and the organelle’s crucial role in apoptosis was identified during the 1990s. Considerable progress has been made in identifying the molecular components of the mitochondrial machinery responsible for life and cell death; however, effective therapies for diseases caused by mitochondrial dysfunction remain elusive. An impediment to manipulating, probing and assessing the functional components of mammalian mitochondria within living cells is their limited accessibility to direct physical, biochemical and pharmacological manipulation. Recent advances in nanotechnology hold the promise of helping to overcome these obstacles. New tools will undoubtedly emerge, creating new avenues for the diagnosis and therapy of mitochondrial disorders. This review briefly discusses current efforts to merge nanobiotechnology with mitochondrial medicine.
Collapse
|